USO DO SIROLIMO NAS MALFORMAÇÕES LINFÁTICAS

Abstract

Lymphatic malformations are a group of pathologies with different clinical presentations, ranging from aesthetic involvement to complex functional dysfunctions. The therapeutic options available range from drugs to surgical interventions, but with unsatisfactory levels of clinical response. Sirolimus or rapamycin is a drug used for immunosuppressive purposes in transplant recipients, especially in the pediatric population. In recent years, evidence has emerged that the use of this drug is highly effective, at levels far superior to conventional treatments. Its antiangiogenic potential is the object of study in several types of lesions, including lymphangiomas. Through a literature review, 10 publications were selected on the PubMed platform, which met the descriptors “((rapamycin) OR (sirolimus) OR (mTOR)) AND (lymphatic malformations)”. The data brought by the authors were analyzed according to the year of publication, title, abstract, methodology and conclusion. Thus, this work seeks to compile reliable and relevant information on the therapeutic proposal of this group of diseases through the use of sirolimus.